search
Back to results

Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease

Primary Purpose

Alzheimer's Disease, Memory Decline

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Panax Ginseng
Sponsored by
Seoul National University Hospital
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Alzheimer's Disease focused on measuring Alzheimer's disease, Ginseng, CD34

Eligibility Criteria

40 Years - 83 Years (Adult, Older Adult)Female

Inclusion Criteria:

  • Alzheimer's disease

Exclusion Criteria:

  • other neurologic disease

Sites / Locations

    Outcomes

    Primary Outcome Measures

    Cognitive performances monitored by MMSE and Alzheimer's disease assessment scales.
    Biomarkers including hematopoietic progenitor cell count.

    Secondary Outcome Measures

    Full Information

    First Posted
    October 22, 2006
    Last Updated
    October 22, 2006
    Sponsor
    Seoul National University Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00391833
    Brief Title
    Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2006
    Overall Recruitment Status
    Completed
    Study Start Date
    April 2004 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    October 2005 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Seoul National University Hospital

    4. Oversight

    5. Study Description

    Brief Summary
    We investigate the clinical efficacy of Panax ginseng in Alzheimer's disease (AD).
    Detailed Description
    Alzheimer's disease (AD) is characterized by a progressive decline of memory and intellectual abilities, interfering activity in daily living, the overall quality of life, and ultimately leads to death. Although pharmacologic treatments are currently approved for treating mild- to moderate AD using acetylcholinesterase inhibitors (ACEI) or memantine, the NMDA antagonist, for the advanced stage of AD, the therapeutic efficacies need to be further improved. For millennia, ginseng or its components have been used to treat medical conditions, and the pharmacologic effects have been demonstrated in cardiovascular, endocrine and immune system (Attele et al., 1999). In means of memory and learning, a number of studies suggested that ginseng can attenuate learning deficits of damaged or ageing brains in rodent models (Kennedy et al., 2003; Zhao and McDaniel, 1998; Nitta et al., 1995). In studies with human healthy participants, correspondently, both acute and chronic dosage of ginseng increased the cognitive performance (Kennedy et al., 2001; Kennedy et al., 2003; D'Angelo et al., 1986; Sorensen and Sonne, 1996). In this study, we we will investigate the contribution of ginseng treatment in increasing the cognitive improvement of AD patients. In addition, we will test various bio-markers and hematopoietic progenitor cell count in those included patients using their blood samples. Patients with AD as well as memory decline will be included

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Alzheimer's Disease, Memory Decline
    Keywords
    Alzheimer's disease, Ginseng, CD34

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1, Phase 2
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    Non-Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Panax Ginseng
    Primary Outcome Measure Information:
    Title
    Cognitive performances monitored by MMSE and Alzheimer's disease assessment scales.
    Title
    Biomarkers including hematopoietic progenitor cell count.

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    40 Years
    Maximum Age & Unit of Time
    83 Years
    Eligibility Criteria
    Inclusion Criteria: Alzheimer's disease Exclusion Criteria: other neurologic disease
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Manho Kim, MD, PhD
    Organizational Affiliation
    Department of Neurology, Seoul National University Hospital
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    18580589
    Citation
    Lee ST, Chu K, Sim JY, Heo JH, Kim M. Panax ginseng enhances cognitive performance in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008 Jul-Sep;22(3):222-6. doi: 10.1097/WAD.0b013e31816c92e6.
    Results Reference
    derived

    Learn more about this trial

    Effect of Panax Ginseng on the Cognitive Performance in Alzheimer's Disease

    We'll reach out to this number within 24 hrs